The ser9gly SNP in the dopamine D3 receptor causes a shift from cAMP related to PGE2 related signal transduction mechanisms in transfected CHO cells

Journal of Medical Genetics

Volumn 41, Issue 11, 2004, Pages 867-871

  Hellstrand, Monika ^a,c   Danielsen, E A ^b   Steen, V M ^b   Ekman, A ^a   Eriksson, E ^a   Nilsson, C L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c NONE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA TOXIN; CYCLIC AMP; DOPAMINE; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; ETICLOPRIDE; FORSKOLIN; HALOPERIDOL; ISOBUTYLMETHYLXANTHINE; PERTUSSIS TOXIN; PROSTAGLANDIN E2; RACLOPRIDE; SPIPERONE;

ANIMAL CELL; ARTICLE; CHO CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INDUCED DISEASE; GENETIC TRANSFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RADIOASSAY; RECEPTOR DENSITY; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TARDIVE DYSKINESIA;

AMINO ACID SUBSTITUTION; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DINOPROSTONE; DOPAMINE; GLYCINE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SERINE; SIGNAL TRANSDUCTION; TRANSFECTION;

ANIMALIA;

EID: 8744230049     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2004.020941     Document Type: Article

References (45)

1. 3H]spiperone binding. Naunyn Schmiedebergs Arch Pharmacol 1998;358:342-50.
2. 3 receptor in schizophrenia and in antipsychotic drug actions. Brain Res Rev 2000;31:277-87.
3. 3 receptor agents as potential new medications for drug addiction. Eur Psychiatry 2000;15:140-6.
4. 3 receptor dependent potentiation of arachidonic acid release. J Neurochem 1992;59:379-82.
5. 2+-mobilizing agent. Br J Pharmacol 1998;124:1651-8.
6. 2+ mobilizing agent. Biochem Pharmacol 2002;63:2151-8.
7. 2 dopamine receptor expressed in CHO cells. FEBS Lett 1993;324:81-6.
8. 3 receptor expressed in transfected cell lines. Eur J Pharmacol 1994;266:79-85.
9. 3 dopamine receptor. J Pharmacol Exp Ther 1994;268:417-26.
10. 3 receptor. Life Sci 1999;64:939-51.
11. 3 receptors expressed in Chinese hamster ovary (CHO) cells. Biochem Pharmacol 1999;58:285-9.
12. 3 receptors in Chinese hamster ovary cells. J Pharmacol Exp Ther 1999;290:908-16.
13. 3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 1992;2:249-56.
14. 3 receptor gene. J Med Genet 1992;29:858-60.
15. 3 ser9gly polymorphisms. Am J Med Genet 1998;81:24-8.
16. 3 gene and schizophrenia: ethnic heterogeneity and significant association in Caucasians. Am J Med Genet 1998;81:318-22.
17. 3 receptor gene variant and susceptibility to tordive dyskinesia in schizophrenic patients. Mol Psychiatry 1997;2:139-45.
18. 3 receptor gene ser9gly polymorphism. Neuropsychopharmacol 2002;27:105-19.
19. 3 associated with tordive dyskinesia in humans. Pharmacogenomics J 2003;3:97-100.
20. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-82.
21. 3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia. Am J Med Genet 2004;124B:1-5.
22. 3 receptor gene polymorphism and violent behavior: relation to impulsiveness and ADHD-related psychopathology. J Neural Transm 2003;110:561-72.
23. 3 and risk of avoidant and obsessive personality traits and disorders. Psychiatry Res 2003;119:1-10.
24. 3 receptor with the Semliki Forest virus system. Biochem Biophys Res Commun 1996;225:1068-72.
25. 2 dopamine receptors. Mol Pharmacol 1994;45:51-60.
26. 3 dopamine receptors. Cell Mol Neurobiol 2002;22:47-56.
27. 2 dopamine receptor missense variants. J Biol Chem 1996;271:26013-17.
28. i coupling. J Biol Chem 2000;275:38518-23.
29. Fukunaga K, Ishii S, Asano K, Yokomizo T, Shiomi T, Shimizu T, Yamaguchi K. Single nucleotide polymorphism of human platelet-activating factor receptor impairs G-protein activation. J Biol Chem 2001;276:43025-30.
30. 1A receptor. Neuropsychopharmacol 1997;17:18-26.
31. Kenakin T. Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 2001;15:598-611.
32. Brydon L, Petit L, de Coppet P, Barrett P, Morgan PJ, Strosberg AD, Jockers R. Polymorphism and signalling of melatonin receptors. Reprod Nutr Dev 1999;39:315-24.
33. 2 dopamine receptors. Biochemistry 1993;32:8179-83.
34. 1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol 2002;39:155-60.
35. Pang RT, Ng SS, Cheng CH, Hollmann MH, Miller LJ, Chow BK. Role of N-linked glycosylation on the function and expression of the human secretin receptor. Endocrinology 1999;140:5102-11.
36. 2A adrenergic receptors. Br J Pharmacol 1999;126:939-48.
37. 1 dopamine receptor binding and signal transduction. Mol Pharmacol 1996;50:1338-45.
38. Green KA, Cottrell GA. Modulation of ligand-gated dopamine channels in Helix neurones. Pflügers Arch 1997;434:313-22.
39. 1 -adrenoceptor. Mol Pharmacol 2003a;63:1312-21.
40. 2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 2003b;64:1357-69.
41. Costall B, Holmes SW, Kelly ME, Noylor RJ. Modification of dyskinesias following the intrastriatal injection of prostaglandins in the rodent. Br J Pharmacol 1985;85:943-9.
42. Schwarz RD, Uretsky NJ, Bianchine JR. Prostaglandin inhibition of apomorphine-induced circling in mice. Pharmocol Biochem Behav 1982;17:1233-7.
43. Ono N, Abiru T, Sugiyama K, Kamiya H. Influences of cyclooxygenase inhibitors on the cataleptic behavior induced by haloperidol in mice. Prostaglandins Leukot Essent Fatty Acids 1992;46:59-63.
44. Muller N, Riedel M, Scheppoch C, Brandstatter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Moller HJ, Schwarz MJ. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159: 1029-34.
45. Bennett CN, Horrobin DF. Gene targets related to phospholipid and fatty acid metabolism in schizophrenia and other psychiatric disorders: an update. Prostaglandins Leukot Essent Fatty Acids 2000;63:47-59.